CellCentric at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
CellCentric exhibits at Booth 301, 305 at ASH 2026 in New Orleans. CellCentric supports a symposium on relapsed and refractory multiple myeloma, run by PeerView Institute for Medical Education. It looks at how to sequence T-cell engagers, newer CAR-T therapies and drugs that work in new ways.
| Organization | ASH 2026 Attendance |
|---|---|
CellCentric Cambridge, United Kingdom | |
Biotechnology company developing inobrodib, an oral p300/CBP inhibitor, for multiple myeloma and other cancers. | Booth Exhibiting at Booth 301, 305 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. |
Find decision makers at CellCentric
Tell us what you sell and we’ll find the people at CellCentric most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction